Vibativ
Evidence Grade A — Regulatory approved. 461 published studies. 16 registered clinical trials.
Loading...
Telavancin (sold as Vibativ) is an intravenous antibiotic derived from vancomycin with enhanced potency, approved for complicated skin infections and hospital-acquired pneumonia caused by gram-positive bacteria including MRSA. It combines two killing mechanisms — blocking cell wall construction and disrupting the bacterial membrane — for faster bacterial killing than vancomycin alone.
461 published studies: 325 human, 29 animal, 138 in-vitro, 162 reviews
Telavancin is marketed as Vibativ (approved September 2009 for skin infections; June 2013 for hospital-acquired pneumonia). It is administered as a once-daily intravenous infusion.
In skin infection trials, telavancin was non-inferior to vancomycin. In hospital-acquired pneumonia, it showed a trend toward superiority in the S. aureus subgroup. However, telavancin carries a boxed warning regarding foetal risk and a risk of kidney toxicity — patients with pre-existing kidney disease (creatinine clearance below 50 mL/min) had increased mortality in clinical trials. These safety concerns, combined with the availability of other options, have limited its clinical uptake compared to daptomycin and the longer-acting lipoglycopeptides.
Telavancin combines two killing mechanisms. Like vancomycin, it blocks cell wall construction by binding to D-Ala-D-Ala, but approximately 14 times more potently. Uniquely, its lipophilic side chain also inserts into the bacterial membrane, causing rapid depolarisation — the membrane loses its electrical charge, which is essential for the bacterium's energy production and nutrient transport. This dual attack (cell wall plus membrane) produces faster bacterial killing than vancomycin alone.
Phase III trials involving approximately 3,300 patients showed telavancin was non-inferior to vancomycin for skin infections and showed a trend toward superiority in pneumonia caused by S. aureus. However, a three-component boxed warning has significantly limited its use: increased mortality in patients with pre-existing kidney disease, direct kidney toxicity, and risk of harm to unborn babies. These safety concerns, combined with the availability of other effective options (daptomycin, dalbavancin, oritavancin), have relegated telavancin to a niche role — typically reserved for gram-positive infections where other options have failed or are not suitable. It also interferes with coagulation blood tests and causes a distinctive metallic or soapy taste. No paediatric data are available.
Telavancin Blood and Cerebrospinal Fluid Concentrations in Patients With External Ventricular Drainage
Telavancin Pharmacokinetics in Cystic Fibrosis Patients
Pharmacokinetics of Telavancin in Normal and Obese Subjects
Effect of Dialysis on the Pharmacokinetics of Telavancin in Patients With Chronic Kidney Disease Stage 5
Telavancin Pediatric PK Study (Ages >12 Months to 17 Years)
FDA ORIG 1
FDA SUPPL 2
EMA Marketing Authorisation
FDA SUPPL 4
FDA SUPPL 6
FDA SUPPL 3
FDA SUPPL 8
FDA SUPPL 7
FDA SUPPL 9
FDA SUPPL 10
FDA SUPPL 11
FDA SUPPL 13
FDA SUPPL 12
FDA SUPPL 14
FDA SUPPL 15
FDA SUPPL 16
Corticotropin is marketed as H.P. Acthar Gel (currently ANI Pharmaceuticals). It carries approximately 19 FDA-labelled indications including infantile spasms (its strongest evidence base), nephrotic syndrome, multiple sclerosis relapses, and rheumatic disorders. Acthar Gel has been at the centre of major pricing and legal controversies. The price rose from approximately $40 per vial in 2001 to over $40,000, driven by successive acquisitions and orphan-like positioning despite broad labelling. The former manufacturer Mallinckrodt agreed to a $260 million settlement over antitrust concerns. Clinically, the strongest evidence supports its use in infantile spasms, where it is considered a first-line treatment. For most other indications, debate continues over whether it offers meaningful advantages over far less expensive oral corticosteroids.
Enfuvirtide is marketed as Fuzeon (approved March 2003). It requires twice-daily subcutaneous injections, and injection-site reactions occur in nearly all patients (98%). In clinical trials (TORO-1 and TORO-2), enfuvirtide combined with an optimised background regimen achieved significantly greater viral suppression than background regimen alone in treatment-experienced patients. Enfuvirtide represented a major advance when HIV drug resistance was a more pressing clinical challenge, but its use has declined substantially with the arrival of more convenient oral antiretrovirals. The twice-daily injection burden, injection-site reactions, high cost, and complex manufacturing (it is one of the largest synthetic peptides manufactured at scale) have limited its role to a last-resort option for patients with highly resistant HIV.
Vancomycin is marketed as Vancocin and Firvanq (approved 1958, with oral solution Firvanq approved 2018). It is the standard treatment for serious MRSA infections (bloodstream infections, endocarditis, pneumonia, bone infections) and is first-line for severe C. difficile colitis. Vancomycin requires therapeutic drug monitoring — blood levels must be checked regularly to ensure the dose is effective without causing kidney damage or hearing loss. The rise of vancomycin-resistant enterococci (VRE) and occasional vancomycin-intermediate S. aureus (VISA) strains represent ongoing challenges. Despite being nearly 70 years old, vancomycin remains irreplaceable for many serious infections, though newer alternatives like daptomycin and the lipoglycopeptides offer advantages in specific settings.
